Koers Emmaus Life Sciences, Inc. Other OTC
Aandelen
EMMA
US29137T1016
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 20,61 mln. 19,28 mln. | Omzet 2022 | 18,39 mln. 17,2 mln. | Marktkapitalisatie | 12,9 mln. 12,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -15 mln. -14,03 mln. | Nettowinst (verlies) 2022 | -10 mln. -9,35 mln. | EV/omzet 2021 | 4,97 x |
Nettoschuld 2021 | 20,13 mln. 18,83 mln. | Nettoschuld 2022 | 28,8 mln. 26,93 mln. | EV/omzet 2022 | 2,27 x |
K/w-verhouding 2021 |
-5,16
x | K/w-verhouding 2022 |
-1,21
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 48,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
George Sekulich
PSD | President | 59 | 01-05-19 |
Willis Lee
CHM | Chairman | 64 | 17-07-19 |
Yasushi Nagasaki
DFI | Director of Finance/CFO | 57 | 01-05-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Wei Peu Zen
BRD | Director/Board Member | 71 | 17-07-19 |
Willis Lee
CHM | Chairman | 64 | 17-07-19 |
Ian Zwicker
BRD | Director/Board Member | 77 | 17-07-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |